DFO
VKTX icon

Duquesne Family Office’s Viking Therapeutics VKTX Stock Holding History

Duquesne Family Office’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-549,295
Closed -$14.6M – 95
2025
Q2 		$14.6M Buy
+549,295
New +$14.5M 0.36% 54

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Duquesne Family Office's VKTX Position: Q3 2025 in Review

Duquesne Family Office sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 549,295 shares — an estimated $14.6M sold.

Duquesne Family Office first reported a position in VKTX in Q2 2025 and held it in 1 quarter. The position peaked at $14.6M in Q2 2025. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

  • Duquesne Family Office reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Duquesne Family Office sold 549,295 Viking Therapeutics shares in Q3 2025, an estimated $14.6M.
  • Duquesne Family Office first reported a position in Viking Therapeutics in Q2 2025 and held it in 1 quarter.
  • Duquesne Family Office's Viking Therapeutics position peaked at $14.6M in Q2 2025.
  • 370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Duquesne Family Office's 13F filing for Q3 2025, filed 14 Nov 2025.